Posts tagged: ARV

Study Reveals HIV-Positive Women Uneasy in the Consulting Room

When people go to see a doctor it is usually to seek help and advice. To find that help, patients overcome some of their fears and pour out their hearts. They never give it a second thought knowing that what is said in the doctors’ office should stay there under the doctor-patient confidentiality. These are based on the fact that doctors should maintain a professional and highly ethical rapport with their patients, uphold their dignity and respect their privacy.

Yet sadly, when it comes to women living with HIV, things aren’t so peachy. Results from a study indicate that many of them do not discuss issues pertaining to their HIV status and important issues like HIV management before or after pregnancy1. Apparently, clinicians have a lack of experience, comfort or knowledge when it came to discussing gender based matters. In the cases that this wasn’t true it was found that the attending clinicians expected these matters to be dealt with by other physicians. Read more »

Vitalwave™ – An Overview

Vitalwave™ is the application of photodisinfection to the birth canal. It is a therapy currently under development by OrGenX Biopharma Corporation and Ondine Biomedical Inc. for the prevention of mother-to-child transmission (PMTCT) of HIV. More than 90% of HIV infections in children are caused by mother-to-child transmission. This is the equivalent of 1,600 children becoming infected with HIV every day, or one child every minute1, affecting 1 out of every 4 babies born. Vitalwave™ is intended to bypass the stigma associated with AIDS, and designed to be safe, instantly effective and inexpensive to allow for universal deployment in resource-poor counties.

It is estimated that 13-38% of all pregnant women in South Africa are HIV positive1. Current estimates indicate that 90% of HIV-positive women in resource-poor settings do not have access to antiretroviral (ARV) medication on a regular basis and often reject treatment due to fear of the stigma-related threats of violence and abandonment. In the absence of ARV treatment, a pregnant woman has a 14-42% chance of passing HIV on to their child during labour and delivery2. A higher HIV vaginal viral load in the mother is associated with an increased risk of transmission to their unborn child. Vitalwave™ is currently being designed to safely and immediately reduce the HIV vaginal viral load to low levels.

Read more »

International AIDS Society (IAS) Conference – Day 3

During today’s plenary session we heard HIV experts from Australia, the Ivory Coast and Belgium.  Susan Kippax (Australia) talked about the social barriers to effective HIV prevention.  She argued that any prevention plan will require people to change their social practices.  Additionally, she presented the case that people’s behavior cannot be separated from their social, cultural and political structure and the biomedical pieces of prevention planning cannot be separated from the non-biomedical ones.  As such, Kippax voiced the requirement that social scientists be part of the discussion when creating HIV prevention plans and policy. Read more »

International AIDS Society (IAS) Conference – Day 2

The venue for the 2011 International AIDS Society Conference is Rome’s music auditorium.  There are four main music halls being used simultaneously to host main sessions.  Delegates sit in acoustically optimized rooms as though they were attending a symphony or ballet, but the music and dancing on the stages is being carried out by the international leaders in HIV/AIDS research and clinical practice.  After the Day 1 festivities, the conference is in full swing and the venue is abuzz with science.

The plenary sessions each day set the stage for the future conference sessions.  Monday’s plenary session featured three presentations; 1) looking at the current state of vaccine development, 2) managing treatment of HIV/AIDS in 2011 and 3) using combination therapies for prevention. Read more »

Mother-to-Child Transmission of HIV: Development of Infant Drug Resistance

In September of 2000, the General Assembly of the United Nations held the Millennium Summit to adopt an “Earth Charter” and a “Declaration” that would lead to global governance.  The summit focused on the role of the United Nations in the 21st century; in particular, the UN’s role in pulling over one billion people out of extreme poverty, halting the pandemic of HIV/AIDS and protecting the global environment.  With 150 heads of state in attendance, it was the largest gathering of world leaders in history as of 2000; the outcome of this summit was eight international development objectives known as the UN Millennium Goals.  Two of these goals expressed an intention by the year 2015 to reverse the spread of HIV/AIDS1 and to reduce by 66% the infant mortality rate 2.

Using a class of pharmaceutical drugs known as anti-retrovirals (ARVs), great strides have been made toward achieving these UN Millennium Goals.  However, each year approximately 300,000 infants still contract HIV/AIDS 3.  Almost all of these HIV+ infants are infected through mother-to-child transmission, and in the absence of treatment,  half will die before the age of two.  Using ARV therapy, the total rate of mother-to-child transmission (MTCT) can be reduced to between two and five percent (without treatment, rates are between 20-45%) 4.   Read more »

Related Posts Plugin for WordPress, Blogger...

Staypressed theme by Themocracy